Companies / Paradox Immunotherapeutics
Paradox Immunotherapeutics
United States
Paradox Immunotherapeutics develops specialized antibodies to selectively target problematic proteins that cause protein misfolding diseases
Paradox Immunotherapeutics, based in United States, has 3 investors on file, among them Creative Destruction Lab, Springboard and SymBiosis Capital Management. Its site was last checked 6 Nov 2026: site answers.
Investors
3 investors on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Accelerator | |
| Portfolio page | Accelerator | |
| Portfolio page | Venture capital |
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Paradox Immunotherapeutics and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Creative Destruction Lab adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/paradoximmuno.com/investors
# also
GET /v1/companies/paradoximmuno.com
GET /v1/companies/paradoximmuno.com/news